PL360915A1 - Zastosowanie rozpuszczalnych kostymulujących cząsteczek w celu wzmocnienia odpowiedzi immunologicznych - Google Patents

Zastosowanie rozpuszczalnych kostymulujących cząsteczek w celu wzmocnienia odpowiedzi immunologicznych

Info

Publication number
PL360915A1
PL360915A1 PL36091500A PL36091500A PL360915A1 PL 360915 A1 PL360915 A1 PL 360915A1 PL 36091500 A PL36091500 A PL 36091500A PL 36091500 A PL36091500 A PL 36091500A PL 360915 A1 PL360915 A1 PL 360915A1
Authority
PL
Poland
Prior art keywords
immune responses
costimulatory molecules
enhance immune
soluble costimulatory
soluble
Prior art date
Application number
PL36091500A
Other languages
English (en)
Inventor
Knut Sturmhoefel
Stanley F. Wolf
Margot O'toole
Original Assignee
Genetics Institute, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Llc filed Critical Genetics Institute, Llc
Publication of PL360915A1 publication Critical patent/PL360915A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
PL36091500A 1999-05-06 2000-05-05 Zastosowanie rozpuszczalnych kostymulujących cząsteczek w celu wzmocnienia odpowiedzi immunologicznych PL360915A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06
PCT/US2000/012435 WO2000067788A2 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses

Publications (1)

Publication Number Publication Date
PL360915A1 true PL360915A1 (pl) 2004-09-20

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36091500A PL360915A1 (pl) 1999-05-06 2000-05-05 Zastosowanie rozpuszczalnych kostymulujących cząsteczek w celu wzmocnienia odpowiedzi immunologicznych

Country Status (15)

Country Link
EP (1) EP1181053A2 (pl)
JP (1) JP2002544170A (pl)
KR (1) KR20020001865A (pl)
CN (1) CN1377279A (pl)
AU (1) AU4825700A (pl)
BR (1) BR0010711A (pl)
CA (1) CA2373256A1 (pl)
CZ (1) CZ20013964A3 (pl)
HK (1) HK1041810A1 (pl)
HU (1) HUP0201222A3 (pl)
IL (1) IL146106A0 (pl)
NO (1) NO20015396L (pl)
PL (1) PL360915A1 (pl)
WO (1) WO2000067788A2 (pl)
ZA (1) ZA200109376B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US7683200B2 (en) * 2005-06-30 2010-03-23 Eisai R & D Management Co., Ltd. Compounds for preparing immunological adjuvant
JP2009521409A (ja) 2005-12-08 2009-06-04 ユニバーシティー オブ ルーイビル リサーチ ファンデーション，インコーポレーテッド 制御性ｔ細胞を増殖する方法と組成物
KR20080090412A (ko) * 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 생체내 세포 표면 엔지니어링
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
AU2013243922A1 (en) * 2012-04-02 2014-10-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN110743006B (zh) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 用于协同解除免疫细胞衰竭的组合物及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521053A (ja) * 1998-07-28 2002-07-16 マイクロメット アーゲー ヘテロミニ体

Also Published As

Publication number Publication date
WO2000067788A3 (en) 2001-04-05
ZA200109376B (en) 2003-03-13
HK1041810A1 (zh) 2002-07-26
IL146106A0 (en) 2002-07-25
AU4825700A (en) 2000-11-21
NO20015396D0 (no) 2001-11-05
KR20020001865A (ko) 2002-01-09
WO2000067788A2 (en) 2000-11-16
BR0010711A (pt) 2002-02-13
JP2002544170A (ja) 2002-12-24
CZ20013964A3 (cs) 2002-06-12
HUP0201222A2 (en) 2002-08-28
CN1377279A (zh) 2002-10-30
NO20015396L (no) 2002-01-02
CA2373256A1 (en) 2000-11-16
EP1181053A2 (en) 2002-02-27
HUP0201222A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
IL146106A0 (en) Use of soluble costimulatory molecules to enhance immune responses
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
IL144578A0 (en) Antibodies specific to kdr and uses thereof
HUP0200898A2 (en) Derivatives of venlafaxine and methods of preparing and using the same
HUP0302352A3 (en) Sn-38 lipid complexes and methods of use
HUP0100623A3 (en) Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
AU2605501A (en) Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions
HK1050013A1 (zh) 抗人IL-1β抗體
AU8390301A (en) Antibodies to human MCP-1
AU2002228890A1 (en) Use of zwitterionic polysaccharides for the specific modulation of immune processes
AU2086501A (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide andnucleic acid compositions
AU4988000A (en) Immune stimulating dietary supplement and methods of use thereof
IL149614A0 (en) Novel use of antibodies as vaccines
HK1044817A1 (en) Use of 13c-nmr to detect binding
AU3179999A (en) Methods to treat undesirable immune responses
AU2002249917A1 (en) Induction of immune responses to isoaspartyl-modified antigens
AU5801398A (en) The use of cd4-binding small molecules to inhibit immune responses
IL157614A0 (en) Uses of opg ligand to modulate immune responses
AU6019599A (en) Use of mcrp to enhance immune responses
AU2001261133A1 (en) Detection of antibodies to gangliosides
EP1071459A4 (en) METHOD FOR EXCITING IMMUNE REACTIONS AGAINST CANCER
PL346796A1 (en) Methods of downmodulating the immune response to therapeutic proteins
AUPP942099A0 (en) Improvements to cooking apparatus
AU6074000A (en) Human immune response molecules
GB9926227D0 (en) Garments designed to adhere to similar garments

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)